Quercetin promotes degradation of survivin and thereby enhances death-receptor- mediated apoptosis in glioma cells

Neuro-Oncology

Volumn 11, Issue 2, 2009, Pages 122-131

  Siegelin, Markus D ^a   Reuss, David E ^a   Habel, Antje ^a   Rami, Abdelhaq ^b   Von Deimling, Andreas ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Glioma; Quercetin; Survivin; TRAIL

Indexed keywords

DEATH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUERCETIN; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REGULATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; FLOW CYTOMETRY; GLIOMA; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 65949095390     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-085     Document Type: Article

References (44)

1. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8(8):808-815.
2. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 1996;85(6):803-815.
3. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD- homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 1996;85(6):817-827.
4. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 2002;16(1): 33-45.
5. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10(1):66-75.
6. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or- death switch. Nat Rev Cancer. 2002;2(9):647-656.
7. Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther. 2003;2(4 suppl 1):S105-S114.
8. Roth W, Isenmann S, Naumann U, et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun. 1999;265(2):479-483.
9. de Vries EG, Gietema JA, de Jong S. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res. 2006;12(8):2390-2393.
10. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Onco- gene. 2001;20(41):5789-5798.
11. Röhn TA, Wagenknecht B, Roth W, et al. CCNU-dependent poten- tiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene. 2001;20(31):4128- 4137.
12. Ng CP, Bonavida B. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand- mediated apoptosis of prostate cancer cells in the presence of mito- chondrial activation: sensitization by overexpression of second mito- chondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO). Mol Cancer Ther. 2002;1(12):1051-1058.
13. Griffith TS, Fialkov JM, Scott DL, et al. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 2002;62(11):3093-3099.
14. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999;11(1):68-75.
15. Deveraux QL, Reed JC. IAP family proteins-suppressors of apopto- sis. Genes Dev. 1999;13(3):239-252.
16. Liston P, Young SS, Mackenzie AE, Korneluk RG. Life and death deci- sions: the role of the IAPs in modulating programmed cell death. Apoptosis. 1997;2(5):423-441.
17. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promis- ing therapeutic target. Apoptosis. 2001;6(4):253-261.
18. Wagenknecht B, Glaser T, Naumann U, et al. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ. 1999;6(4):370-376.
19. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003;3(10):768-780.
20. Surh YJ, Ferguson LR. Dietary and medicinal antimutagens and anti- carcinogens: molecular mechanisms and chemopreventive potential- highlights of a symposium. Mutat Res. 2003;523-524:1-8.
21. Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of car- cinogenesis by dietary polyphenolic compounds. Annu Rev Nutr. 2001;21:381-406.
22. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52(4):673-751.
23. Watson WH, Cai J, Jones DP. Diet and apoptosis. Annu Rev Nutr. 2000;20:485-505.
24. Ong CS, Tran E, Nguyen TT, et al. Quercetin-induced growth inhibi- tion and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expres- sions. Oncol Rep. 2004;11(3):727-733.
25. Shen SC, Chen YC, Hsu FL, Lee WR. Differential apoptosis-inducing effect of quercetin and its glycosides in human promyeloleukemic HL-60 cells by alternative activation of the caspase 3 cascade. J Cell Biochem. 2003;89(5):1044-1055.
26. Singhal RL, Yeh YA, Praja N, Olah E, Sledge GW Jr, Weber G. Quer- cetin down-regulates signal transduction in human breast carcinoma cells. Biochem Biophys Res Commun. 1995;208(1):425-431.
27. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, sur- vivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917-921.
28. Siegelin M, Touzani O, Toutain J, Liston P, Rami A. Induction and redistribution of XAF1, a new antagonist of XIAP in the rat brain after transient focal ischemia. Neurobiol Dis. 2005;20(2):509-518.
29. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin- proteasome pathway regulates survivin degradation in a cell cycle- dependent manner. J Cell Sci. 2000;113(pt 23):4363-4371.
30. Ferry DR, Smith A, Malkhandi J, et al. Phase I clinical trial of the fla- vonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996;2(4):659-668.
31. Koschny R, Ganten TM, Sykora J, et al. TRAIL/bortezomib cotreat- ment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology. 2007;45(3):649-658.
32. Koschny R, Holland H, Sykora J, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Can- cer Res. 2007;13(11):3403-3412.
33. Kim YH, Lee YJ. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem. 2007;100(4):998-1009.
34. Chen W, Wang X, Zhuang J, Zhang L, Lin Y. Induction of death recep- tor 5 and suppression of survivin contribute to sensitization of TRAIL- induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis. 2007;28(10):2114-2121.
35. Hao C, Beguinot F, Condorelli G, et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res. 2001;61(3):1162-1170.
36. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 1998;427(1):124-128.
37. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the X-linked inhibitor of apoptosis (XIAP)- XAF1 complex. J Biol Chem. 2007;282(36):26202-26209.
38. Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphati- dylinositol 3-kinase. Cell. 1995;81(5):727-736.
39. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death pro- tease caspase-9 by phosphorylation. Science. 1998;282(5392):1318-1321.
40. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96(6):857-868.
41. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Ele- vated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem. 2001;276(14):10767-10774.
42. Papapetropoulos A, Fulton D, Mahboubi K, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem. 2000;275(13):9102-9205.
43. Granado-Serrano AB, Martín MA, Bravo L, Goya L, Ramos S. Querce- tin induces apoptosis via caspase activation, regulation of Bcl-2, and inhibition of PI-3-kinase/Akt and ERK pathways in a human hepatoma cell line (HepG2). J Nutr. 2006;136(11):2715-2721.
44. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol. 2005;25(20):8809-8823.